Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

Abstract excerpt

BACKGROUND: The detection of V600E BRAF mutations has fundamental clinical consequences as the treatment option with BRAF inhibitors such as vemurafenib or dabrafenib yields response rates of ~48%. Heterogeneity with respect to BRAF mutation in different metastases has been described in single cases. As this has important implications for the determination of BRAF status and treatment of patients, it is essential...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Metastases and Treatment
• Share to Cutaneous Melanoma Detection and Management
• Share to Melanoma and MAPK Pathways